Picture loading failed.

Anti-ERBB3 therapeutic antibody (Pre-made Elgemtumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Elgemtumab, also known as LJM716, is a high- affinity IgG1κ type monoclonal antibodies selected from a Human Combinatorial Antibody Library (HuCAL). It can specifically bind to ERBB3 to neutralize multiple modes of ERBB3 activation.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-170-1mg 1mg 3090
GMP-Bios-ab-170-10mg 10mg 21890
GMP-Bios-ab-170-100mg 100mg 148000
GMP-Bios-ab-170-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ERBB3 therapeutic antibody (Pre-made Elgemtumab biosimilar,Whole mAb)
INN Name Elgemtumab
TargetERBB3
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4p59:HL
Year Proposed2014
Year Recommended2015
CompaniesMorphoSys;Novartis;Memorial Sloan-Kettering Cancer Center;Novartis Oncology
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer;Gastric cancer;Head and neck cancer;Oesophageal cancer;Solid tumours
Development TechMedarex HuMAb Mouse